Fujifilm Rebrands Life Sciences Group with New Unified Identities

• Fujifilm Corporation has rebranded its Life Sciences Group companies under a unified strategic framework.

• FUJIFILM Irvine Scientific becomes FUJIFILM Biosciences, while FUJIFILM Diosynth Biotechnologies is now FUJIFILM Biotechnologies.

FUJIFILM Corporation has announced the rebranding of its Life Sciences Group companies as part of a broader strategic alignment aimed at offering end-to-end solutions across the drug development lifecycle. The company’s updated identity structure is designed to support therapeutic development from discovery through to commercialisation.

The move sees FUJIFILM Irvine Scientific renamed as FUJIFILM Biosciences, effective immediately, with a legal name change scheduled for 1 January 2026. The business, headquartered in Santa Ana, California, reflects its growth from a cell culture media pioneer to a broader provider of discovery reagents, proteins, chemicals, and assay materials.

Meanwhile, FUJIFILM Diosynth Biotechnologies, a global CDMO, will now operate under the name FUJIFILM Biotechnologies. The legal name remains unchanged. This entity continues to provide contract manufacturing services from process development to commercial supply across Europe and the U.S.

According to the press release, these changes come after more than $10 billion in investment over 15 years into the life sciences segment, driven by Fujifilm’s ambition to accelerate access to advanced care solutions.

“By redefining our Life Sciences Group, we also support Fujifilm’s growth strategy for the life sciences sector,” said Toshihisa Iida, director and corporate vice president at FUJIFILM Corporation.

The rebrand is part of a wider effort under the ‘Partners for Life’ banner, aiming to simplify customer engagement and foster collaboration across Fujifilm’s global network of pharmaceutical and biotechnology partners.